BB Biotech discloses 0.6% stake in Yarrow Bioscience
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
BB Biotech disclosed a 0.6% position in clinical-stage biotech Yarrow Bioscience in its third-quarter report. The stake follows Yarrow's recent public offering, which raised Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context